Evaluation of $^{99m}$Tc-3PRGD$_2$ integrin receptor imaging in hepatocellular carcinoma tumour-bearing mice: comparison with $^{18}$F-FDG metabolic imaging

Jieling Zheng $^1$ · Weibing Miao $^1$ · Chao Huang $^1$ · Haoxue Lin $^1$

Received: 30 March 2017 / Accepted: 17 April 2017 / Published online: 4 May 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Objective Our study was designed to explore the utility of $^{99m}$Tc-HYNIC-PEG$_4$-[PEG$_4$-c(RGDfK)$_2$]$_3$ ($^{99m}$Tc-3PRGD$_2$) for the detection of hepatocellular carcinoma (HCC) and specifically to compare the diagnostic performance of $^{99m}$Tc-3PRGD$_2$ integrin receptor imaging and 2-18-fluoro-2-deoxy-D-glucose ($^{18}$F-FDG) metabolic imaging in a nude mouse model.

Methods $^{99m}$Tc-3PRGD$_2$ was synthesized using a HYNIC-3PRGD$_2$ lyophilized kit with $^{99m}$TcO$_4$ labelling. The nude mouse animal model was established by subcutaneously injecting $5 \times 10^7$ ml HepG2 cells into the shoulder flank of each mouse. Biodistribution studies were performed at 0.5, 1, 2 and 4 h after intravenous administration of 0.37 MBq of $^{99m}$Tc-3PRGD$_2$. Immunohistochemistry was performed to evaluate the expression level of integrin $\alpha_v\beta_3$ in the HCC tissues. Dynamic imaging was performed using list-mode after the administration of 55.5 MBq of $^{99m}$Tc-3PRGD$_2$, to reconstruct the multiphase images and acquire the best initial scan time. At 8, 12, 16, 20 and 24 days after inoculation with HepG2 cells, 55.5 MBq of $^{99m}$Tc-3PRGD$_2$ and 37 MBq of $^{18}$F-FDG were injected successively into the nude mouse model, subsequently, simultaneous SPECT/PET imaging was performed to calculate the tumour volume and tumour uptake of $^{99m}$Tc-3PRGD$_2$ and $^{18}$F-FDG.

Results The biodistribution study first validated that the tumour uptake of $^{99m}$Tc-3PRGD$_2$ at the different time points was higher than that of all the other organs tested in the experiment, except for the kidney. Integrin $\alpha_v\beta_3$ expressed highly in early stage HCC and declined for further necrosis of the tumour tissue. Subcutaneous tumours were visualized clearly with excellent contrast under $^{99m}$Tc-3PRGD$_2$ SPECT/CT imaging, and the multiphase imaging comparison showed the tumours were prominent at 0.5 h, suggesting that the best initial scan time is 0.5 h post-injection. The comparison of the imaging results of the two methods showed that $^{99m}$Tc-3PRGD$_2$ integrin receptor imaging was more sensitive than $^{18}$F-FDG metabolic imaging for the detection of early stage HCC, meanwhile the uptake of $^{99m}$Tc-3PRGD$_2$ was consistently higher than that of $^{18}$F-FDG. However, as tumour necrosis further increased in HCC tissues, the uptake of $^{18}$F-FDG was higher than that of $^{99m}$Tc-3PRGD$_2$. Conclusion Our study demonstrated that $^{99m}$Tc-3PRGD$_2$ is a valuable tumour molecular probe for the detection of early stage HCC, meriting further investigation of $^{99m}$Tc-3PRGD$_2$ as a novel SPECT tracer for tumour imaging.

Keywords $^{99m}$Tc-3PRGD$_2$ · Hepatocellular carcinoma · Integrin $\alpha_v\beta_3$ · $^{18}$F-FDG

Introduction

Hepatocellular carcinoma (HCC) is a primary cancer of the liver with a significant impact worldwide due to its high incidence and mortality. Early detection and diagnosis of HCC can bring great benefit for the prognosis of patients. Currently, the definitive diagnosis of HCC depends primarily on conventional imaging modalities, such as ultrasound, magnetic resonance imaging or computed...
tomography [1]. However, these techniques are usually based on anatomical, morphological or haemodynamic alterations. The appearance of HCC at the early stage is atypical, and thus, there is no obvious difference between small HCC and preneoplastic nodules. Moreover, the types of hepatic lesions are complicated, various forms of inflammation, granulomatous lesions and benign tumours can mimic the morphology and haemodynamics of early HCC, resulting in the difficult differential diagnosis of early HCC in non-cirrhotic patients. Therefore, conventional imaging modalities still have some limitation in the diagnosis of early HCC.

Hepatocarcinogenesis is considered a multi-step process; changes firstly come from gene, molecule and metabolic function, with subsequent anatomical and morphological changes. Hence, acquiring cellular, molecular or functional information on HCC tumours through functional imaging techniques has significant clinical value for the early detection and diagnosis of HCC. Nowadays, 2-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT is the most widely employed tumour-functional imaging modality worldwide, however, the positive detection rate for HCC is still not ideal, particularly in terms of the low specificity and sensitivity for the detection of early stage HCC [2, 3]. Thus, a large number of other compounds have been investigated as an alternative or complement to 18F-FDG, most recently 11C-acetate [4, 5], 11C-choline [6], and 18F-labelled fluorothymidine [7, 8]; however, none of these compounds have gained broad approval. Accordingly, there is still a distinct need for better functional imaging modalities available for patients with HCC.

Integrin αvβ3, a member of the integrin receptor family, is highly expressed in both tumour cells and activated endothelial cells and plays a pivotal role in tumour growth, invasion and metastasis [9–11]. The tri-peptide sequence of arginine-glycine-aspartic acid (RGD) is a cellular recognition site that can selectively bind to integrin αvβ3 [12]. A variety of radiolabeled RGDs have been developed as SPECT and PET radiotracers for tumour imaging and have attracted considerable attention in recent decades. Our study was designed to investigate the feasibility of 99mTc-HYNIC-PEG4-E[PEG4-c(RGDfK)]2 (99mTc-3PRGD2) for the detection of HCC and specifically to compare the diagnostic performance of 99mTc-3PRGD2 integrin receptor imaging and 18F-FDG metabolic imaging in HCC tumour-bearing mice.

Materials and methods

Radiopharmaceutical preparation

The HYNIC-3PRGD2 lyophilized kit was obtained from the Medical Isotope Research Center of Peking University. The synthesis of the labelling precursor and subsequent 99mTc-labelling were performed according to previously described methods [13]. The vial containing the above product was heated at 100 °C for 20 min and then incubated at room temperature for 10 min. The resulting solution was analysed using radioactive thin layer chromatography to verify that the radiochemical purity was >95%. 18F-FDG was supplied by the Atom High-tech Company of China (Fuzhou, Fujian, China). Doses were prepared by dissolving the radiotracer in saline.

Animal model

This study was approved by our hospital’s Ethics Committee for medical research. A total of 36 female athymic nu/nu mice were purchased from the Medical Animal Center, FuZhou General Hospital of Nanjing Military Command (6-week-old, average body weight 24.16 ± 2.28 g). The human HCC HepG2 cell line was purchased from the Institute of Cytobiology, Chinese Academy of Science. The HepG2 cells were cultured in DMEM supplemented with 10% foetal bovine serum (FBS, HyClone) and 1% penicillin and streptomycin solution (Gibco) at 37 °C in a humidified atmosphere of 5% CO2 in air. The cells were split or harvested when they reached 90–100% confluency to maintain exponential growth. Each mouse was implanted subcutaneously with 5 × 107/ml HepG2 cells into the left shoulder flank. The tumour volume was measured every other day with vernier callipers and calculated using the following formula: (length × width2)/2.

Biodistribution study

A total of 16 HepG2 hepatoma-bearing mice, with a maximum tumour diameter of 1.0 cm, were randomly divided into 4 groups, with 4 animals in each group. Each mouse was injected intravenously with 0.37 MBq of 99mTc-3PRGD2 in 0.1 ml. At 0.5, 1, 2 and 4 h after administration, the mice were sacrificed by humane euthanasia, and the important organs (tumour, heart, liver, spleen, lungs, kidneys, stomach, intestine, muscle and blood) were excised, dried, weighed and counted using a γ-counter. The percentage of the injected dose per gram (%ID/g) and the target/non-target (T/NT) ratios were calculated to evaluate the biological distribution characteristics of 99mTc-3PRGD2 in the nude mice.

Immunohistochemistry

In total, 12 mice were chosen randomly for HepG2 cell inoculation at different time points. When the subcutaneous tumours grew to various sizes (0.06–1.0 g), the mice were sacrificed by humane euthanasia, and the tumours were

\[ \text{Ann Nucl Med (2017) 31:486–494} \]
excised, fixed in 10% formalin, embedded in paraffin, cut into slices (6-μm-thick) and dried. After dewaxing in xylene and hydrating in gradient ethyl alcohol (from 100 to 80%), the sections were incubated with the mouse anti-integrin αvβ3 monoclonal antibody (1:100, Abcam, Cambridge, USA), followed by sequential incubation with reagent A (reaction enhancer) and B (enzyme-conjugated goat anti-mouse/rabbit IgG polymer) of an immunohisto-chemical EliVision plus kit, then washed with phosphate buffer solution (PBS) and stained with fresh diaminobenzidine (DAB) solution. Finally, the sections were visualized under an Olympus optical microscope (Olympus Corporation, Tokyo, Japan). The appearance of brown colouring in the cytoplasm or cytomembrane of the tumour tissues was regarded as positive integrin αvβ3 expression.

**Dynamic SPECT/CT imaging with 99mTc-3PRGD2**

All imaging studies were performed using microSPECT/PET/CT equipment (Versatile Emission Computed Tomography System, Milabs, Utrecht, the Netherlands), which enables simultaneous submillimeter imaging of single-photon and positron-emitting radiolabeled molecules. Four HepG2 hepatoma-bearing mice were injected with 55.5 MBq of 99mTc-3PRGD2 in 0.1 ml saline via the tail vein. At 20 min after administration, the mice were quickly transferred into a shielded chamber connected to an isoflurane anaesthesia unit. After the induction of anaesthesia, the mice were immediately placed supine on the scanning bed. The 99mTc-3PRGD2 imaging commenced 30 min after the tracer injection. First, rectangular scans in the regions of interest (ROIs) from both the SPECT and CT were selected by X-ray. CT scanning was performed using the “normal” acquisition settings at 55 keV and 615 μA, and then SPECT data were acquired from 30 min to 3 h and 4 to 4.5 h post-injection (pi) in list-mode using the following settings: 84 projections per frame over 30 min and a 20% energy window centred on 140 keV.

**Multiphase image reconstruction and data analysis**

CT reconstruction was performed using a cone-beam filtered back-projection algorithm (NRecon v1.6.3, Skyscan, Belgium). SPECT image reconstruction of the list-mode raw data was performed using a pixel-based ordered-subsets expectation maximization algorithm (POSEM), with the initial scan time set as 0.5, 1, 2 and 4 h pi (a 30-min scanning time). The new SPECT data and CT data were fused together using PMOD software (PMOD Technologies, Zurich, Switzerland). To achieve a higher signal-to-noise ratio, Gaussian smooth 3D (1.0 mm full-width at half maximum) was used and the image colour gradation was adjusted. For each SPECT/CT fusion image, the ROI covering the entire tumour was generated automatically by setting a maximum pixel value threshold of 30% or more, and then the tumour volume and radioactivity counts were calculated using PMOD. The tumour uptake of 99mTc-3PRGD2 was expressed as the percentage of the injected dose (%ID) and the percentage of the injected dose per unit volume (%ID/cm³). The background ROI (0.01 cm³) was drawn over the muscle of the contralateral forelimb, and then the T/NT ratio of tumour to muscle was calculated for the semi-quantitative analysis.

**Simultaneous SPECT/PET Imaging with the 99mTc/18F dual-isotope**

The HepG2 hepatoma-bearing mice were reared at 26–27 °C. Four mice were chosen for simultaneous SPECT/PET imaging at 8, 12, 16, 20 and 24 days after inoculation with HepG2 cells, and they were fasted but allowed to drink water for 12 h before imaging. The selected mice were injected intravenously with 55.5 MBq of 99mTc-3PRGD2 and 37 MBq of 18F-FDG successively. A 45-min simultaneous SPECT/PET acquisition was obtained, beginning at 45 min after the tracer injection. Throughout the scanning, the body temperature of the mice was monitored using a constant heating and feedback device. To achieve signal separation of the two tracers, the energy peak was set to 140 keV for 99mTc-3PRGD2 and 511 keV for 18F-FDG. All photopeak windows were set to a width of 20%. The SPECT and PET images were reconstructed using POSEM. The tumour volume and tumour uptakes of 99mTc-3PRGD2 and 18F-FDG (%ID and %ID/cm³) were calculated using PMOD software.

**Statistical analyses**

The quantitative data are expressed as x ± s. The statistical analyses were performed using one-way analysis of variance (ANOVA) for multiple comparisons, least significant difference (LSD) t test for the comparisons between groups and regression analyses for the correlation analysis with the SPSS 18.0 statistical software package. The level of significance was set at P < 0.05.

**Results**

**Biodistribution of 99mTc-3PRGD2**

As shown in Fig. 1a, the tumour uptake of 99mTc-3PRGD2 at the different time points was 4.301 ± 0.313 %ID/g (0.5 h), 6.902 ± 0.717 %ID/g (1 h), 5.045 ± 0.193 %ID/g (2 h) and 2.099 ± 0.388 %ID/g (4 h), with a statistically
significant difference between each group \((F = 78.864, P < 0.05)\). \(^{99}\text{Tc}\)-3PRGD\(_2\) was primarily excreted through the urinary system as evidenced by the higher renal uptake \((11.842 \pm 1.304, 10.034 \pm 1.051, 8.683 \pm 0.437, 4.225 \pm 0.332 \% \text{ID/g} \text{ at 0.5, 1, 2 and 4 h pi, respectively})\). Moderate accumulation was also found in the intestine and liver, illustrating that \(^{99}\text{Tc}\)-3PRGD\(_2\) was partially metabolized by the liver or intestine. Other organs with relatively low radioactivity were the spleen, lung, stomach, blood and muscle. Figure 1b shows the \(T/NT\) ratios of tumour to muscle and tumour to liver, indicating that the highest \(T/NT\) ratios were obtained at 2 h pi \((9.57 \pm 2.37 \text{ and } 2.56 \pm 0.91, \text{ respectively})\).

**Integrin \(\alpha\beta_3\) expression in HCC tissues**

HCC cells have large and atypical nuclei and mitosis in haematoxylin-eosin (HE)-stained slices. Immunohistochemistry showed that integrin \(\alpha\beta_3\) positive expression, as visualized by brown staining, was observed predominantly in the cytoplasm and cytomembrane, as well as the vascular epithelial cells (Fig. 2). The expression level of \(\alpha\beta_3\) in HCC cells varied among the different tumour sizes \((0.06–1.0 \text{ g})\). When the tumour weight was less than 0.23 g without tumour necrosis, the overall expression level of \(\alpha\beta_3\) was relatively high. When the tumour weight was between 0.35 and 1.0 g, the expression level of integrin \(\alpha\beta_3\) gradually declined in line with the necrosis of the HCC tissues.

**Dynamic SPECT/CT imaging results**

The subcutaneous tumours were clearly visualized under multiphase SPECT/CT imaging, with excellent contrast at 0.5, 1, 2 and 4 h pi (Fig. 3). The accumulation of radioactivity in the subcutaneous tumours was most obvious when the initial scan time was 0.5 h pi, and some radionuclide remained until 4 h pi. Prominent renal uptake of \(^{99}\text{Tc}\)-3PRGD\(_2\) was observed at all time points examined, whereas abdomen uptake was moderate and radioactivity accumulation in the lung, mediastinum and muscle was relatively low. Furthermore, radioactivity distribution in all body tissue types decreased over time. These results were consistent with that of the biodistribution study.

The tumour uptake was \(4.61 \pm 1.17 \% \text{ID/cm}^3 \text{ (0.5 h), } 3.61 \pm 0.87 \% \text{ID/cm}^3 \text{ (1 h), } 3.02 \pm 0.75 \% \text{ID/cm}^3 \text{ (2 h) and } 2.63 \pm 0.71 \% \text{ID/cm}^3 \text{ (4 h)}\), suggesting that the highest tumour uptake occurred when the initial scan time
was 0.5 h pi. The T/NT ratios of tumour to muscle were 3.39 ± 1.33 (0.5 h), 3.17 ± 1.33 (1 h), 3.66 ± 0.92 (2 h) and 2.86 ± 0.49 (4 h). Although the highest T/NT ratio was found when the initial scan time was 2 h pi, there were no statistically significant differences among the four groups (P > 0.05). Both the direct visualization and quantitative analysis indicated that the best initial scan time was 0.5 h pi.

**Fig. 2** Representative microscopic images of the tumour slices from the different sized xenografted HepG2 tumours after haematoxylin-eosin (HE) staining and immunohistochemical staining (0.09 and 0.35 g). a HE staining showed the HCC cells and tumour blood vessels without tumour necrosis. b Immunohistochemistry showing the positive expression of integrin αvβ3 was visualized as brown staining. The results showed that αvβ3 was predominantly expressed in the cytoplasm and cytomembrane, as well as the vascular epithelial cells (arrows). c HE staining showing the central visual field was characterized by cell necrosis. d Immunohistochemistry showing that αvβ3 staining was negative in the necrotic region. The images were obtained by an Olympus optical microscope (10 × 20 magnification).

**Fig. 3** Traverse views (a) and coronal views (b) of multiphase SPECT/CT images after the injection of 55.5 MBq of 99mTc-3PRGD2 in HepG2 hepatoma-bearing mice, with the initial scan time set as 0.5, 1, 2 and 4 h pi (a 30-min scanning time).
Multimodal imaging of HCC with the $^{99m}$Tc/$^{18}$F dual-isotope

We assessed the performance differences between $^{99m}$Tc-3PRGD$_2$ integrin receptor imaging and $^{18}$F-FDG metabolic imaging during the growth of tumour with the micro-SPECT/PET/CT system (Fig. 4). $^{99m}$Tc-3PRGD$_2$ SPECT/CT could sensitively detect subcutaneous tumours at 8 days after inoculation with HepG2 cells. The tumours were clearly visualized at 8, 12, and 16 days after inoculation with HepG2 cells for the distinct concentration and homogenous distribution of radionuclides, and the tumour volume gradually increased over time. In contrast, there was only minimal uptake in the subcutaneous tumours under $^{18}$F-FDG PET/CT imaging at 8, 12, and 16 days after inoculation with HepG2 cells. From day 20 to day 24, as tumour necrosis further increased, both the $^{99m}$Tc-3PRGD$_2$ SPECT/CT fusion images and $^{18}$F-FDG PET/CT fusion images showed uneven tracer distribution in the HCC tissues. Notably, the uptake of $^{18}$F-FDG into the brown adipose tissue located in the neck and back or multiple muscle tissues was too high, thereby affecting image quality and forcing some measures including warming, fasting and anaesthesia to be performed in advance.

Comparison of tumour uptake of $^{99m}$Tc-3PRGD$_2$ and $^{18}$F-FDG

The tumour uptake of $^{99m}$Tc-3PRGD$_2$ and $^{18}$F-FDG at the different imaging time points is shown in Table 1. Except for the uptake measurements on day 20 ($P < 0.05$), there were no statistically significant differences among the different groups, which were divided according to the imaging day ($t = 1.62, P < 0.05$). A regression analysis was used to assess the relationship between the tumour volume and tumour uptake of $^{99m}$Tc-3PRGD$_2$ and $^{18}$F-FDG (Fig. 5). The relationship between the tumour volume and %ID of $^{99m}$Tc-3PRGD$_2$ was modelled as quadratic polynomial, with an $R^2$ value of 0.85. The conversion formula was $y = -17.81x^2 + 11.16x - 0.38$, indicating that the uptake of $^{99m}$Tc-3PRGD$_2$ increased to its peak as the tumour volume increased and then declined due to necrosis (day 24). The relationship between the tumour volume and %ID of $^{18}$F-FDG was also modelled as quadratic polynomial, with an $R^2$ value of 0.96. The conversion formula was $y = -6.61x^2 + 7.68x - 0.18$, illustrating that the tumour uptake of $^{18}$F-FDG was consistently less than that of $^{99m}$Tc-3PRGD$_2$ from day 8 to day 16. When all the tumour volume was greater than 0.30 cm$^3$ from day 20 to day 24, the uptake of $^{18}$F-FDG, in turn, was higher than that of $^{99m}$Tc-3PRGD$_2$ during this time period.

Discussion

Among the various forms of radioactive medications, $^{99m}$Tc-3PRGD$_2$ stands out for its superior $\alpha_v\beta_3$-targeting ability, biodistribution and pharmacokinetics [13–15]. It has been shown to be a promising tracer for the diagnosis, staging, and treatment evaluation of thoracic malignancies.
such as lung cancer, breast cancer and metastasis [16–19].
However, few studies have investigated the use of 99mTc-3PRGD2 for the diagnosis of HCC, especially no studies have compared the efficacy of 99mTc-3PRGD2 integrin receptor imaging with 18F-FDG metabolic imaging. Integrin \( \alpha_v \beta_3 \) express lowly in normal liver tissues including hepatocytes, stellate cells, Kupffer cells, and other non-parenchymal cells [20]. Studies have reported that the expression of integrin \( \alpha_v \beta_3 \) is significantly higher in HCC tissues than in adjacent normal hepatic tissue [21]. In this study, we demonstrated that HCC could be detected using SPECT/CT with 99mTc-3PRGD2 as the radiotracer.

To further estimate the usefulness of 99mTc-3PRGD2 in the non-invasive monitoring of HCC tumours, 18F-FDG was chosen as the positive control. The imaging results indicated that 99mTc-3PRGD2 SPECT/CT has an advantage over 18F-FDG PET/CT for HCC imaging in two aspects. First, 99mTc-3PRGD2 SPECT/CT could distinctly and sensitively detect the HCC tissues at 8 days after HepG2 cell inoculation, a time point at which the smallest tumour volume was only 0.041 cm\(^3\) but the uptake of 99mTc-3PRGD2 reached 10.67 %ID/cm\(^3\) at this point. In contrast, the tumours were unclear under 18F-FDG images so the imaging could not be used to accurately detect early stage HCC. Furthermore, the tumour uptake of 99mTc-3PRGD2 was significantly higher than that of 18F-FDG from day 8 to day 16. This finding suggests that 99mTc-3PRGD2 has the potential to be used as a SPECT tracer for early detection of HCC over 18F-FDG. Second, it is well known that 18F-FDG PET/CT imaging is affected by many factors, such as glucose levels, insulin, and temperature. Muscle or brown adipose tissue can also competitively uptake 18F-FDG [22, 23]. In contrast, 99mTc-3PRGD2 integrin receptor imaging shows less interference from these factors, resulting in the acquisition of clearer images. Moreover, 99mTc-3PRGD2 can be more widely applied to improve the screening rates for early HCC detection because it is more cost-effective, feasible and practical as a SPECT tracer.

We analysed the possible reasons for the different imaging results with 99mTc-3PRGD2 and 18F-FDG comes from two completely different biological processes they are targeting. In this study, we found that \( \alpha_v \beta_3 \) expression in the xenografted HepG2 tumours was high in the early stage and showed an increasing trend until the tumours became necrotic. Given that 99mTc-3PRGD2 is a target-specific radiotracer whose biodistribution is determined by its receptor, the high expression level of \( \alpha_v \beta_3 \) in early HCC contributes to the high tumour uptake of 99mTc-3PRGD2; therefore, 99mTc-3PRGD2 imaging is able to sensitively detect early HCC while 18F-FDG imaging is used to evaluate glucose metabolism, the main mechanism of 18F-FDG uptake in malignant tumours largely depends on the presence of facilitated glucose transporters, especially type 1 (Glut 1) and a rate-limiting glycolytic enzyme, especially hexokinase (HK) type II. However, HCCs have different glucose-regulating mechanisms and enzyme expression

| Tracer           | 8 days   | 12 days  | 16 days  | 20 days  | 24 days  | \( F \)  | \( P \)   |
|------------------|----------|----------|----------|----------|----------|---------|----------|
| 99mTc-3PRGD2     | 0.48 ± 0.03 | 0.79 ± 0.23 | 1.51 ± 0.12 | 1.65 ± 0.14 | 1.17 ± 0.06 | \( F = 52.73 \) | \( P < 0.05 \) |
| 18F-FDG         | 0.25 ± 0.06 | 0.43 ± 0.12 | 1.04 ± 0.14 | 1.80 ± 0.12 | 1.88 ± 0.15 | \( F = 153.20 \) | \( P < 0.05 \) |
patterns, and the low expression of Glut 1 and the existence of dephosphorylase are the main reasons for the low $^{18}$F-FDG uptake [24–26]. The uptake of $^{18}$F-FDG in HCC is also related to the degree of differentiation and lesion size, with well-differentiated HCC exhibiting a high rate of gluconeogenesis compared with that in normal liver tissues, resulting in similar uptake of $^{18}$F-FDG [27]. In particular, early stage HCC tumours, which are well differentiated and small in size, show low radioactivity concentrations under $^{18}$F-FDG PET/CT imaging.

Except $^{99m}$Tc-3PRGD$_2$ SPECT/CT was more sensitive than $^{18}$F-FDG PET/CT for the detection of early HCC, it is worth noting that HCC uptake of $^{18}$F-FDG was higher than that of $^{99m}$Tc-3PRGD$_2$ in advanced stage HCC, indicating that the diagnostic efficiency of $^{18}$F-FDG PET/CT might be better than $^{99m}$Tc-3PRGD$_2$ SPECT/CT for imaging advanced HCC. On one hand, the tumour uptake of $^{99m}$Tc-3PRGD$_2$ may have decreased due to the concomitant maturity of blood vessels, tumour necrosis, and larger interstitial space that accompanied the rapid growth of the tumour [28]. On the other hand, cancer cell growth is heavily dependent on glucose metabolism as a major energy substrate, particularly poorly differentiated advanced HCC. The association of neoplastic growth with increased aerobic glycolysis is known as the Warburg effect, which might help explain why the uptake of $^{18}$F-FDG increased in advanced stage HCC [29]. Therefore, combining $^{99m}$Tc-3PRGD$_2$ SPECT/CT and $^{18}$F-FDG PET/CT imaging could aid in the detection of HCC by compensating for the deficiency of $^{18}$F-FDG in the detection of early stage HCC and $^{99m}$Tc-3PRGD$_2$ in the diagnosis of advanced HCC. Moreover, multimodality imaging using multiple tracers can also provide complementary information on tumour-associated functions with excellent sensitivity and high selectivity; thus, multimodality imaging might improve the tumour diagnosis, differential diagnosis and therapeutic monitoring of HCC compared with those of a single radiological modality alone.

In the complex pathogenesis of hepatic carcinoma, angiogenesis is one of the crucial events, relying on the migration and invasion of vascular endothelial cells, which is regulated by various cell adhesion receptors including the integrin family [30]. Among the 24 members of integrin family, αvβ3 is the most widely studied because its expression is an important factor in determining the invasiveness and metastatic potential of malignancy [11]. In our study, we demonstrated that αvβ3 was highly expressed on the activated endothelial cells of HCC tissues. Currently, sorafenib chemotherapy, an anti-angiogenic therapy, is the first line therapy for HCC patients who are not eligible for surgical removal or liver transplantation. However, there is still no appropriate imaging modality to monitor the efficacy of anti-angiogenic therapy. Research has shown that $^{99m}$Tc-3PRGD$_2$ can be applied to guide anti-angiogenic therapy by visualizing and quantifying the expression level of αvβ3 [18, 31]. Thus, $^{99m}$Tc-3PRGD$_2$ imaging has the potential to select suitable patients who could benefit from sorafenib chemotherapy and supply an objective basis for its curative effect.

It should be noted that our results are preliminary and obtained using a very limited number of animals; therefore, insufficient data may have caused errors in our analysis. Further studies with a substantial number of animals or a comparable translational human clinical trial are still needed. Moreover, most HCCs arise in the setting of chronic hepatitis induced by HCV or HBV infection. However, current animal models cannot mimic the inflammatory microenvironment that leads to the pathogenesis of HCC and the pathogenic sequence of human HCC that starts with fibrosis and cirrhosis prior to the development of HCC. Several studies have reported that $^{99m}$Tc-3PRGD$_2$ can assess activation of hepatic stellate cells and diagnose liver fibrosis [32, 33]. The uptake in normal hepatic, hepatitis and liver fibrosis tissues may decrease the $T/NT$ ratio and influence the detection of HCC. Finally, the relation between the pathologic grade and tumour uptake of $^{99m}$Tc-3PRGD$_2$ was not assessed in the present study; therefore, we cannot verify whether various pathologic types of liver cancer impact $^{99m}$Tc-3PRGD$_2$ SPECT/CT imaging.

In conclusion, $^{99m}$Tc-3PRGD$_2$ is more sensitive for the detection of early stage HCC than $^{18}$F-FDG, but in advanced HCC, the diagnostic performance of $^{18}$F-FDG might be better than that of $^{99m}$Tc-3PRGD$_2$ because the tumour uptake of $^{99m}$Tc-3PRGD$_2$ significantly declined due to tumour necrosis. Combined $^{99m}$Tc-3PRGD$_2$ SPECT/CT and $^{18}$F-FDG PET/CT imaging would be helpful for the imaging diagnosis of HCC. We believe that $^{99m}$Tc-3PRGD$_2$ is worth further investigating as a promising radiotracer for the diagnosis of HCC and guidance of the anti-angiogenic therapy.

**Acknowledgements** The authors thank the Medical Isotopes Research Center of Peking University for supplying the HYNIC-3PRGD2 lyophilized kit. This work was financially supported by the Fujian Provincial Natural Science Foundation (2015J01459) and the Fujian Provincial Medical Innovate Foundation (2015-CX-21).

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**References**

1. Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol. 2015;13:219–34.
2. Khan MA, Combs CS, Brunt EM, Lowe VJ, Wolverson MK, Solomon H, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol. 2000;32:792–7.

3. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510–5.

4. Territo PR, Maluccio M, Rileya AA, Brian P, et al. Evaluation of 11C-Acetate and 18 F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med Imaging. 2015;15:15.

5. Hwang KH, Choi DJ, Lee SY, Lee MK, Choe W. Evaluation of hepatocellular carcinomas using [11C]acetate and [18F]FDG PET/CT: a preliminary study. Appl Radiat Isot. 2009;67:1195–8.

6. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K, Kashiwagi H, Deguchi A, et al. Detection of hepatocellular carcinoma using [11C]-choline PET: comparison with [18F]-FDG PET. J Nucl Med. 2008;49:1245–8.

7. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging. 2006;33:1285–9/.

8. Eckel F, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, et al. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker [18F]-fluorothymidine. J Nucl Med. 2009;50:1441–7.

9. Hodivala-Dilke K. αvβ3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol. 2008;20:514–9.

10. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin αvβ3 antagonism. Anticancer Agents Med Chem. 2006;6:407–28.

11. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569–71.

12. Russolatti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. Science. 1987;238:491–7.

13. Jia B, Liu Z, Zhu Z, Shi J, Jin X, Zhao H, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates. Mol Imaging Biol. 2011;13:730–6.

14. Wang L, Shi J, Kim YS, Zhai S, Jia B, Zhao H, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers. Mol Pharm. 2009;6:231–45.

15. Zhou Y, Kim YS, Chakraborty S, Shi J, Gao H, Liu S. 99mTc-labeled cyclic RGD peptides for noninvasive monitoring of tumor integrin αvβ3 expression. Mol Imaging. 2011;10:386–97.

16. Zhou Y, Shao G, Liu S. Monitoring breast tumor lung metastasis by U-SPECT-II/CT with an integrin αvβ3-targeted radiotracer 99mTc-3PRGD2. Theranostics. 2012;2:577–88.

17. Miao W, Zheng S, Dai H, Wang F, Jin X, Zhu Z, et al. Comparison of 99mTc-3PRGD2 integrin receptor imaging with 99mTc-MDP bone scan in diagnosis of bone metastasis in patients with lung cancer: a multicenter study. PLoS One. 2014;9:e111221.

18. Ma Q, Min K, Wang T, Chen B, Wen Q, Wang F, et al. 99mTc-3PRGD2 SPECT/CT predicts the outcome of advanced nonsquamous non-small cell lung cancer receiving chemoradiotherapy plus bevacizumab. Ann Nucl Med. 2015;29:519–27.

19. Chen Q, Xie Q, Zhao M, Chen B, Gao S, Zhang H, et al. Diagnostic value of 99mTc-3PRGD2 scintimammography for differentiation of malignant from benign breast lesions: comparison of visual and semi-quantitative analysis. J Nucl Med. 2015;18:193–8.

20. Li F, Song Z, Li Q, Wu J, Wang J, Xie C, et al. Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrin αvβ3 expression with SPECT in rat. Hepatology. 2011;54:1020–30.

21. Jin Y, Chen JN, Feng ZY, Zhang ZG, Fan WZ, Wang Y, et al. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. Plos One. 2014;9:e87930.

22. Yeung HWD, Grewal RK, Gonen M, Schöder H, Larson SM. Patterns of 18F-FDG uptake in adipose tissue and muscle: a potential source of false-positive for PET. J Nucl Med. 2003;44:1789–96.

23. Christensen CR, Clark PB, Morton KA. Reversal of hypermetabolic brown adipose tissue in [18F]-FDG PET imaging. Clin Nucl Med. 2006;31:193–6.

24. Lee JD, Yang WI, Park YN, Kim KS, Choi JS, Yun M, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased [18F]-FDG uptake. J Nucl Med. 2005;46:1753–9.

25. Mamede M, Higashi T, Katai M, Ishizu K, Ishimori T, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36:1811–7.

26. Shao G, Zhou Y, Wang F, Liu S. Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin αvβ3. Mol Imaging. 2013;12:39–48.

27. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.

28. Liu S. Radiolabeled cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins. Bioconjug Chem. 2015;26:1413–38.

29. Zhang X, Xin J, Shi Y, Xu W, Yu S, Yang Z, et al. Assessing activation of hepatic stellate cells by 99mTc-3PRGD2 scintigraphy targeting integrin αvβ3: a feasibility study. Nucl Med Biol. 2015;42:1362–70.

30. Yang Z, Xin J, Shi Y, Xu W, Yu S, Yang Z, et al. Assessing activation of hepatic stellate cells by 99mTc-3PRGD2 scintigraphy targeting integrin αvβ3: a feasibility study. Nucl Med Biol. 2015;42:1362–70.